Skip to main content
Premium Trial:

Request an Annual Quote

Other Uses

The mRNA vaccine technology behind some of the authorized SARS-CoV-2 vaccines is also being applied to other diseases, including cancer, CBS Sunday Morning reports.

"We've had an incredible year using messenger RNA to fight a pandemic," Stephen Hoge, the president of Moderna, tells it. "But we think we're just starting in the infectious disease space. And so, there's a large number of other vaccines we're bringing forward."

As CBS Sunday Morning notes, the company is pursuing a vaccine for HIV, aims to streamline the process for making influenza vaccines, and is also developing vaccines for cancers like lymphoma and melanoma. One, for melanoma, is in clinical testing, it adds. BioNTech, which worked with Pfizer on their mRNA-based SARS-CoV-2 vaccine, is similarly seeking to expand its repertoire and is working on a tuberculosis and an HIV vaccine, as the Financial Times noted earlier this month.

At the same time, Moderna is also working on SARS-CoV-2 boosters, which CBS Sunday Morning says it is considering – if boosters are indeed needed – rolling that together with its flu vaccine so that people only need one shot.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.